Back to Search
Start Over
Hydroxyurea use in prevention of stroke recurrence in children with sickle cell disease in a developing country: A cost effectiveness analysis
- Source :
- Pediatric Blood & Cancer. 62:1862-1864
- Publication Year :
- 2015
- Publisher :
- Wiley, 2015.
-
Abstract
- We undertook a cost effectiveness analysis (CEA) of hydroxyurea (HU) in preventing stroke recurrence and/or death. We followed 43 children with sickle cell disease from 2000 to 2009 after having a first clinical stroke, of whom 10 opted for HU therapy. HU use led to decreased stroke recurrence and death without significantly increasing the annual cost of care per patient (J$83,250 vs. J$76,901, P = 0.491). The incremental cost effectiveness ratio (ICER) for prevention of stroke recurrence amounted to J$169,238 (US$1,900), while that for death prevention equalled J$635,843 (US$7,140). HU may be recommended when safe and affordable transfusion therapy is not feasible.
- Subjects :
- medicine.medical_specialty
Stroke recurrence
business.industry
Developing country
Hematology
Disease
Cost-effectiveness analysis
medicine.disease
Oncology
Pediatrics, Perinatology and Child Health
medicine
Physical therapy
Transfusion therapy
Outcomes research
business
Intensive care medicine
Stroke
Incremental cost-effectiveness ratio
Subjects
Details
- ISSN :
- 15455009
- Volume :
- 62
- Database :
- OpenAIRE
- Journal :
- Pediatric Blood & Cancer
- Accession number :
- edsair.doi...........52b263afdd251d938101c3cadb60b1d0